Praluent alirocumab regulatory update

FDA’s Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) will meet on June 9 to discuss a BLA from Sanofi for Praluent alirocumab to treat primary hypercholesterolemia or mixed dyslipidemia...